Highlights
KLSE: DPHARMA (7148)       DUOPHARMA BIOTECH BHD MAIN : Health Care
Last Price Today's Change   Day's Range   Trading Volume
4.01   +0.02 (0.50%)  3.89 - 4.05  7,303,500
Analyze this stock with MQ Trader system

Financials


Market Cap: 2,831 Million

Market Cap 2,831 Million
NOSH 706 Million

Latest Audited Result:  31-Dec-2019

Latest Audited Result: 31-Dec-2019
Announcement Date 30-Apr-2020
Next Audited Result: 31-Dec-2020
Est. Ann. Date: 30-Apr-2021
Est. Ann. Due Date: 29-Jun-2021

Latest Quarter:  30-Jun-2020 [#2]

Latest Quarter: 30-Jun-2020 [#2]
Announcement Date 13-Aug-2020
Next Quarter: 30-Sep-2020
Est. Ann. Date: 29-Nov-2020
Est. Ann. Due Date: 29-Nov-2020
QoQ | YoY   8.61%  |    5.84%

Annual (Unaudited) ( EPS: 7.83, P/E: 51.22 )

Revenue | NP to SH 576,462  |  55,273
RPS | P/RPS 81.65 Cent  |  4.91
EPS | P/E | EY 7.83 Cent  |  51.22  |  1.95%
DPS | DY | Payout % 5.80 Cent  |  1.45%  |  74.06%
NAPS | P/NAPS 0.74  |  5.39
YoY   16.02%
NP Margin | ROE 9.59%  |  10.52%
F.Y. | Ann. Date 31-Dec-2019  |  13-Feb-2020

T4Q Result ( EPS: 7.82, P/E: 51.31 )

Revenue | NP to SH 582,654  |  55,182
RPS | P/RPS 82.53 Cent  |  4.86
EPS | P/E | EY 7.82 Cent  |  51.31  |  1.95%
DPS | DY | Payout % 5.32 Cent  |  1.33%  |  68.02%
NAPS | P/NAPS 0.82  |  4.87
QoQ | YoY   1.50%  |    0.27%
NP Margin | ROE 9.47%  |  9.49%
F.Y. | Ann. Date 30-Jun-2020  |  13-Aug-2020

Annualized Result ( EPS: 8.01, P/E: 50.04 )

Revenue | NP to SH 604,088  |  56,580
RPS | P/RPS 85.56 Cent  |  4.69
EPS | P/E | EY 8.01 Cent  |  50.04  |  2.00%
DPS | DY | Payout % -
NAPS | P/NAPS -
QoQ | YoY   4.31%  |    -0.32%
NP Margin | ROE 9.37%  |  9.73%
F.Y. | Ann. Date 30-Jun-2020  |  13-Aug-2020


Hints :
Click the QoQ or YoY on table to view the QoQ or YoY Financial Result page.

Click here to modify the Visible Columns.

Date Financial Result Financial Ratio Per Share Item Performance Valuation (End of Quarter) Valuation (Ann. Date)
F.Y. Ann. Date Quarter # Revenue PBT NP NP to SH Div Net Worth Div Payout % NP Margin ROE NOSH RPS Adj. RPS EPS Adj. EPS DPS Adj. DPS NAPS Adj. NAPS QoQ YoY EOQ Date EOQ Price EOQ P/RPS EOQ P/EPS EOQ P/NAPS EOQ EY EOQ DY ANN Date ANN Price ANN P/RPS ANN P/EPS ANN P/NAPS ANN EY ANN DY
31-Dec-2020 13-Aug-2020 30-Jun-2020 2 143,331 19,391 14,729 14,729 3,421 581,725 23.23% 10.28% 2.53% 684,383 20.94 20.30 2.15 2.09 0.50 0.48 0.8500 0.82   8.61%   5.84% 30-Jun-2020 1.62 7.74 75.27 1.91 1.33% 0.31% 13-Aug-2020 3.15 15.04 146.36 3.71 0.68% 0.16%
31-Dec-2020 18-May-2020 31-Mar-2020 1 158,713 17,727 13,561 13,561 - 540,662 - % 8.54% 2.51% 684,383 23.19 22.48 1.98 1.92 0.00 0.00 0.7900 0.77   12.70%   -6.25% 31-Mar-2020 1.39 5.99 70.15 1.76 1.43% 0.00% 1.72 7.42 86.80 2.18 1.15% 0.00%
31-Dec-2019 13-Feb-2020 31-Dec-2019 4 137,755 13,939 12,033 12,033 34,114 525,364 283.51% 8.74% 2.29% 682,292 20.19 19.51 1.76 1.70 5.00 4.83 0.7700 0.74   -19.02%   -16.26% 31-Dec-2019 1.42 7.03 80.52 1.84 1.24% 3.52% 13-Feb-2020 1.64 8.12 92.99 2.13 1.08% 3.05%
31-Dec-2019 29-Nov-2019 30-Sep-2019 3 142,855 19,768 14,859 14,859 - 505,919 - % 10.40% 2.94% 674,559 21.18 20.23 2.20 2.10 0.00 0.00 0.7500 0.72   6.78%   20.94% 30-Sep-2019 1.40 6.61 63.56 1.87 1.57% 0.00% 29-Nov-2019 1.39 6.56 63.10 1.85 1.58% 0.00%
31-Dec-2019 30-Aug-2019 30-Jun-2019 2 145,466 18,316 13,916 13,916 6,618 503,029 47.56% 9.57% 2.77% 661,881 21.98 20.60 2.07 1.97 1.00 0.94 0.7600 0.71   -3.80%   34.60% 28-Jun-2019 1.37 6.23 65.16 1.80 1.53% 0.73% 30-Aug-2019 1.41 6.42 67.06 1.86 1.49% 0.71%
31-Dec-2019 21-May-2019 31-Mar-2019 1 150,386 18,786 14,465 14,465 - 496,410 - % 9.62% 2.91% 661,881 22.72 21.30 2.19 2.05 0.00 0.00 0.7500 0.70   0.67%   34.16% 29-Mar-2019 1.28 5.63 58.57 1.71 1.71% 0.00% 21-May-2019 1.36 5.99 62.23 1.81 1.61% 0.00%
31-Dec-2018 18-Feb-2019 31-Dec-2018 4 115,634 17,658 14,369 14,369 26,475 483,173 184.25% 12.43% 2.97% 661,881 17.47 16.38 2.17 2.04 4.00 3.75 0.7300 0.68   16.95%   21.05% 31-Dec-2018 0.95 5.44 43.76 1.30 2.29% 4.21% 18-Feb-2019 1.03 5.90 47.45 1.41 2.11% 3.88%
31-Dec-2018 28-Nov-2018 30-Sep-2018 3 125,838 15,838 12,286 12,286 - 501,487 - % 9.76% 2.45% 659,852 19.07 17.82 1.86 1.74 0.00 0.00 0.7600 0.71   18.83%   7.72% 28-Sep-2018 1.23 6.45 66.06 1.62 1.51% 0.00% 28-Nov-2018 1.07 5.61 57.47 1.41 1.74% 0.00%
31-Dec-2018 26-Nov-2018 30-Jun-2018 2 123,991 12,915 10,339 10,339 4,199 209,983 40.62% 8.34% 4.92% 279,978 44.29 17.56 1.59 1.46 1.50 0.59 0.7500 0.30   -4.11%   7.11% 29-Jun-2018 1.30 2.94 35.20 1.73 2.84% 1.15% 26-Nov-2018 1.08 2.44 29.25 1.44 3.42% 1.39%
31-Dec-2018 28-May-2018 31-Mar-2018 1 133,259 13,255 10,647 10,782 - 206,429 - % 7.99% 5.22% 278,959 47.77 18.87 3.82 1.53 0.00 0.00 0.7400 0.29   -9.17%   25.11% 30-Mar-2018 2.80 5.86 72.44 3.78 1.38% 0.00% 28-May-2018 3.35 7.01 86.67 4.53 1.15% 0.00%
31-Dec-2017 28-Feb-2018 31-Dec-2017 4 112,253 12,825 11,768 11,870 16,737 479,809 141.01% 10.48% 2.47% 278,959 40.24 15.90 4.22 1.68 6.00 2.37 1.7200 0.68   4.08%   40.84% 29-Dec-2017 2.53 6.29 59.46 1.47 1.68% 2.37% 28-Feb-2018 2.97 7.38 69.80 1.73 1.43% 2.02%
31-Dec-2017 17-Nov-2017 30-Sep-2017 3 115,379 14,207 11,127 11,405 - 474,230 - % 9.64% 2.40% 278,959 41.36 16.34 3.99 1.62 0.00 0.00 1.7000 0.67   18.15%   79.86% 29-Sep-2017 2.20 5.32 53.81 1.29 1.86% 0.00% 17-Nov-2017 2.20 5.32 53.81 1.29 1.86% 0.00%
31-Dec-2017 25-Aug-2017 30-Jun-2017 2 117,049 12,642 9,641 9,653 6,973 463,071 72.25% 8.24% 2.08% 278,959 41.96 16.58 3.46 1.37 2.50 0.99 1.6600 0.66   12.01%   114.37% 30-Jun-2017 2.25 5.36 65.02 1.36 1.54% 1.11% 25-Aug-2017 2.03 4.84 58.66 1.22 1.70% 1.23%
31-Dec-2017 22-May-2017 31-Mar-2017 1 120,994 11,176 8,618 8,618 - 463,071 - % 7.12% 1.86% 278,959 43.37 17.14 3.43 1.22 0.00 0.00 1.6600 0.66   2.25%   9.88% 31-Mar-2017 2.31 5.33 74.77 1.39 1.34% 0.00% 22-May-2017 2.32 5.35 75.10 1.40 1.33% 0.00%
31-Dec-2016 24-Feb-2017 31-Dec-2016 4 74,033 6,299 8,831 8,428 11,158 454,703 132.40% 11.93% 1.85% 278,959 26.54 10.49 3.41 1.19 4.00 1.58 1.6300 0.64   32.91%   -45.04% 30-Dec-2016 1.98 7.46 65.54 1.21 1.53% 2.02% 24-Feb-2017 2.23 8.40 73.81 1.37 1.35% 1.79%
31-Dec-2016 21-Nov-2016 30-Sep-2016 3 80,302 7,516 6,226 6,341 - 451,913 - % 7.75% 1.40% 278,959 28.79 11.37 2.23 0.90 0.00 0.00 1.6200 0.64   40.82%   -26.46% 30-Sep-2016 2.06 7.16 90.63 1.27 1.10% 0.00% 21-Nov-2016 2.10 7.30 92.39 1.30 1.08% 0.00%
31-Dec-2016 22-Aug-2016 30-Jun-2016 2 79,135 7,723 3,941 4,503 6,973 446,334 154.87% 4.98% 1.01% 278,959 28.37 11.21 1.41 0.64 2.50 0.99 1.6000 0.63   -42.59%   -23.00% 30-Jun-2016 2.04 7.19 126.38 1.28 0.79% 1.23% 22-Aug-2016 2.14 7.54 132.57 1.34 0.75% 1.17%
31-Dec-2016 18-May-2016 31-Mar-2016 1 79,470 9,941 7,828 7,843 - 457,492 - % 9.85% 1.71% 278,959 28.49 11.26 2.81 1.11 0.00 0.00 1.6400 0.65   -48.86%   -12.55% 31-Mar-2016 2.55 8.95 90.70 1.55 1.10% 0.00% 18-May-2016 2.40 8.42 85.36 1.46 1.17% 0.00%
31-Dec-2015 23-Feb-2016 31-Dec-2015 4 89,401 17,529 17,529 15,335 9,172 270,177 59.82% 19.61% 5.68% 166,776 53.61 12.66 9.19 2.17 5.50 1.30 1.6200 0.38   77.84%   37.92% 31-Dec-2015 2.62 4.89 28.49 1.62 3.51% 2.10% 23-Feb-2016 2.61 4.87 28.39 1.61 3.52% 2.11%
31-Dec-2015 24-Nov-2015 30-Sep-2015 3 79,372 11,621 8,623 8,623 - 268,509 - % 10.86% 3.21% 166,776 47.59 11.24 5.17 1.22 0.00 0.00 1.6100 0.38   47.45%   -0.68% 30-Sep-2015 2.72 5.72 52.61 1.69 1.90% 0.00% 24-Nov-2015 2.70 5.67 52.22 1.68 1.91% 0.00%
31-Dec-2015 25-Aug-2015 30-Jun-2015 2 56,308 8,407 5,848 5,848 5,582 189,815 95.47% 10.39% 3.08% 139,570 40.34 7.98 4.19 0.83 4.00 0.79 1.3600 0.27   -34.80%   -22.16% 30-Jun-2015 2.65 6.57 63.25 1.95 1.58% 1.51% 25-Aug-2015 2.40 5.95 57.28 1.76 1.75% 1.67%
31-Dec-2015 18-May-2015 31-Mar-2015 1 45,599 12,198 8,969 8,969 - 205,045 - % 19.67% 4.37% 139,486 32.69 6.46 6.43 1.27 0.00 0.00 1.4700 0.29   -19.34%   7.22% 31-Mar-2015 3.88 11.87 60.34 2.64 1.66% 0.00% 18-May-2015 3.90 11.93 60.65 2.65 1.65% 0.00%
31-Dec-2014 24-Feb-2015 31-Dec-2014 4 51,024 13,921 13,921 11,119 20,128 192,951 181.02% 27.28% 5.76% 138,813 36.76 7.23 8.01 1.57 14.50 2.85 1.3900 0.27   28.07%   19.39% 31-Dec-2014 2.50 6.80 31.21 1.80 3.20% 5.80% 24-Feb-2015 2.92 7.94 36.45 2.10 2.74% 4.97%
31-Dec-2014 21-Nov-2014 30-Sep-2014 3 44,819 11,287 8,682 8,682 - 187,531 - % 19.37% 4.63% 138,912 32.26 6.35 6.25 1.23 0.00 0.00 1.3500 0.27   15.56%   27.94% 30-Sep-2014 3.17 9.83 50.72 2.35 1.97% 0.00% 21-Nov-2014 3.01 9.33 48.16 2.23 2.08% 0.00%
31-Dec-2014 26-Aug-2014 30-Jun-2014 2 40,623 10,107 7,513 7,513 5,554 179,145 73.94% 18.49% 4.19% 138,872 29.25 5.75 5.41 1.06 4.00 0.79 1.2900 0.25   -10.19%   -29.71% 30-Jun-2014 2.97 10.15 54.90 2.30 1.82% 1.35% 26-Aug-2014 3.37 11.52 62.29 2.61 1.61% 1.19%
31-Dec-2014 20-May-2014 31-Mar-2014 1 40,495 11,175 8,365 8,365 - 190,050 - % 20.66% 4.40% 138,723 29.19 5.74 6.03 1.18 0.00 0.00 1.3700 0.27   -10.18%   24.87% 31-Mar-2014 3.03 10.38 50.25 2.21 1.99% 0.00% 20-May-2014 3.09 10.59 51.24 2.26 1.95% 0.00%
31-Dec-2013 26-Feb-2014 31-Dec-2013 4 45,734 9,160 9,313 9,313 18,737 181,818 201.19% 20.36% 5.12% 138,792 32.95 6.48 6.71 1.32 13.50 2.65 1.3100 0.26   37.24%   55.27% 31-Dec-2013 2.58 7.83 38.45 1.97 2.60% 5.23% 26-Feb-2014 2.60 7.89 38.75 1.98 2.58% 5.19%
31-Dec-2013 19-Nov-2013 30-Sep-2013 3 40,845 9,054 6,786 6,786 - 179,017 - % 16.61% 3.79% 138,773 29.43 5.79 4.89 0.96 0.00 0.00 1.2900 0.25   -36.51%   5.34% 30-Sep-2013 2.55 8.66 52.15 1.98 1.92% 0.00% 19-Nov-2013 2.56 8.70 52.35 1.98 1.91% 0.00%
31-Dec-2013 28-Aug-2013 30-Jun-2013 2 37,988 13,007 10,689 10,689 5,552 187,404 51.95% 28.14% 5.70% 138,818 27.37 5.38 7.70 1.51 4.00 0.79 1.3500 0.27   59.56%   55.66% 28-Jun-2013 2.38 8.70 30.91 1.76 3.24% 1.68% 28-Aug-2013 2.44 8.92 31.69 1.81 3.16% 1.64%
31-Dec-2013 27-May-2013 31-Mar-2013 1 37,837 8,956 6,699 6,699 - 176,143 - % 17.70% 3.80% 138,695 27.28 5.36 4.83 0.95 0.00 0.00 1.2700 0.25   11.69%   -0.13% 29-Mar-2013 2.23 8.17 46.17 1.76 2.17% 0.00% 27-May-2013 2.51 9.20 51.97 1.98 1.92% 0.00%
31-Dec-2012 25-Feb-2013 31-Dec-2012 4 35,378 9,000 5,998 5,998 14,576 169,359 243.02% 16.95% 3.54% 138,819 25.48 5.01 4.32 0.85 10.50 2.06 1.2200 0.24   -6.89%   -5.23% 31-Dec-2012 2.13 8.36 49.30 1.75 2.03% 4.93% 25-Feb-2013 2.17 8.51 50.22 1.78 1.99% 4.84%
31-Dec-2012 23-Nov-2012 30-Sep-2012 3 29,521 8,391 6,442 6,442 - 167,991 - % 21.82% 3.83% 138,836 21.26 4.18 4.64 0.91 0.00 0.00 1.2100 0.24   -6.19%   -14.35% 28-Sep-2012 2.36 11.10 50.86 1.95 1.97% 0.00% 23-Nov-2012 2.28 10.72 49.14 1.88 2.04% 0.00%
31-Dec-2012 16-Aug-2012 30-Jun-2012 2 34,355 9,037 6,867 6,867 4,855 162,310 70.71% 19.99% 4.23% 138,727 24.76 4.87 4.95 0.97 3.50 0.69 1.1700 0.23   2.37%   -0.94% 29-Jun-2012 2.23 9.00 45.05 1.91 2.22% 1.57% 16-Aug-2012 2.38 9.61 48.08 2.03 2.08% 1.47%
31-Dec-2012 17-May-2012 31-Mar-2012 1 36,057 8,869 6,708 6,708 - 170,824 - % 18.60% 3.93% 138,881 25.96 5.11 4.83 0.95 0.00 0.00 1.2300 0.24   5.99%   13.23% 30-Mar-2012 2.40 9.24 49.69 1.95 2.01% 0.00% 17-May-2012 2.38 9.17 49.28 1.93 2.03% 0.00%
31-Dec-2011 22-Feb-2012 31-Dec-2011 4 33,036 7,836 6,329 6,329 20,125 163,776 317.98% 19.16% 3.86% 138,793 23.80 4.68 4.56 0.90 14.50 2.85 1.1800 0.23   -15.85%   -26.53% 30-Dec-2011 2.02 8.49 44.30 1.71 2.26% 7.18% 22-Feb-2012 2.12 8.91 46.49 1.80 2.15% 6.84%
31-Dec-2011 21-Nov-2011 30-Sep-2011 3 36,767 9,726 7,521 7,521 - 162,353 - % 20.46% 4.63% 138,763 26.50 5.21 5.42 1.07 0.00 0.00 1.1700 0.23   8.50%   -1.29% 30-Sep-2011 2.10 7.93 38.75 1.79 2.58% 0.00% 21-Nov-2011 2.10 7.93 38.75 1.79 2.58% 0.00%
31-Dec-2011 18-Aug-2011 30-Jun-2011 2 35,345 9,292 6,932 6,932 4,862 154,198 70.14% 19.61% 4.50% 138,917 25.44 5.01 4.99 0.98 3.50 0.69 1.1100 0.22   17.02%   -5.12% 30-Jun-2011 2.34 9.20 46.89 2.11 2.13% 1.50% 18-Aug-2011 2.22 8.73 44.49 2.00 2.25% 1.58%
31-Dec-2011 25-May-2011 31-Mar-2011 1 32,984 7,875 5,924 5,924 - 162,320 - % 17.96% 3.65% 138,735 23.77 4.67 4.27 0.84 0.00 0.00 1.1700 0.23   -31.23%   15.48% 31-Mar-2011 2.35 9.88 55.04 2.01 1.82% 0.00% 25-May-2011 2.57 10.81 60.19 2.20 1.66% 0.00%
31-Dec-2010 23-Feb-2011 31-Dec-2010 4 32,195 8,607 8,614 8,614 152 156,744 1.77% 26.76% 5.50% 138,711 23.21 4.56 6.21 1.22 0.11 0.02 1.1300 0.22   13.06%   9.82% 30-Dec-2010 2.39 10.30 38.49 2.12 2.60% 0.05% 23-Feb-2011 2.45 10.56 39.45 2.17 2.53% 0.04%
31-Dec-2010 26-Nov-2010 30-Sep-2010 3 34,464 10,221 7,619 7,619 - 148,494 - % 22.11% 5.13% 138,779 24.83 4.88 5.49 1.08 0.00 0.00 1.0700 0.21   4.28%   9.96% 30-Sep-2010 2.44 9.83 44.44 2.28 2.25% 0.00% 26-Nov-2010 2.38 9.58 43.35 2.22 2.31% 0.00%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.


NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ Δ & YoY Δ figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.


Trade this stock with T+7 trading account. Find out more.
  8 people like this.
 
bigby7 Tomorrow need to run already.

https://www.thestar.com.my/news/world/2020/10/21/five-south-koreans-die-after-getting-flu-shots-sparking-vaccine-fears
21/10/2020 8:03 PM
Yu_and_Mee Why run. You all must stay to support your vaccine counters, tp 99.99
21/10/2020 8:07 PM
bigby7 Then you stay la. The rest of us will run.
21/10/2020 8:09 PM
GorengHealthcare ok la glove sell down day red sea; at least have DP as contra to show green in portfolio
21/10/2020 8:20 PM
Chong1116 Bigby7@ that’s yesterday news. The mention cases is not product China vaccine. Tomorrow is back on track, going uptrend!
21/10/2020 8:39 PM
Secret Let see if break new high
21/10/2020 9:11 PM
Carlson Choo bigby7 Tomorrow need to run already.

https://www.thestar.com.my/news/world/2020/10/21/five-south-koreans-di...

hrmm do you know what is FLU VACCINE and Covid VACCINE?

if you dun know please just sell , we will collect.
21/10/2020 9:38 PM
jiasyn Flu vaccine not Covid vaccine.

Please sell, I will collect.
21/10/2020 9:48 PM
napnap Rise too high already
21/10/2020 9:51 PM
napnap From 1.16 in mar till now only 7 MTHS,rise near rm3!! Triple
21/10/2020 9:59 PM
napnap Watch road Bros n sis
21/10/2020 10:00 PM
denzadesu lol,
when up,
spread fear,
want cheap,
typical.

china lead vaccine,
can u not see, their daily cases not increase,
how come they can control the virus, with their population,
of course they have something up their sleeve
21/10/2020 10:27 PM
fizz27 https://www.washingtonpost.com/health/2020/10/21/vaccine-progress-coronavirus/

“Going from where we were in January and February — where we are going to be hit by this tsunami — to very likely having a vaccine, or more than one vaccine, that is proven safe and effective within a year, is staggeringly impressive, and would only have happened with strong and effective federal action,” said Robert Wachter, the chair of the department of medicine at the University of California at San Francisco.”
21/10/2020 11:23 PM
fizz27 https://www.washingtonpost.com/health/2020/10/21/vaccine-progress-coronavirus/

“Going from where we were in January and February — where we are going to be hit by this tsunami — to very likely having a vaccine, or more than one vaccine, that is proven safe and effective within a year, is staggeringly impressive, and would only have happened with strong and effective federal action,” said Robert Wachter, the chair of the department of medicine at the University of California at San Francisco.”
21/10/2020 11:23 PM
Warrantchampion CE will go furthest to 20 sen...CF has greatest value can reach 28 sen. Huat all
21/10/2020 11:31 PM
Warrantchampion Conservative estimates for cw above when mother reach RM 4.5
21/10/2020 11:31 PM
BetterNation napnap From 1.16 in mar till now only 7 MTHS,rise near rm3!! Triple

Hi napnap , in my humble opinion, if you look many other counters not only healthcare but tech and etc are all raise 100% after dip on March , so we can only consider this stock raise double, not triple theoretically. Chase high is fine you are chasing a stock with exponential growth with right amount of capital, if you can read Chinese, even before having the opportunity to work on vaccine, the company already has great prospect - https://klse.i3investor.com/blogs/sinchew_company_story/2020-09-01-story-h1512633115.jsp
21/10/2020 11:43 PM
bigby7 https://www.aljazeera.com/economy/2020/10/21/brazils-president-slams-vaccine-after-health-ministry-buys-it
22/10/2020 1:51 AM
henry888 i don't trust any news from aljazeera. com. regarding China as she is pro US. Again, the president of Brazil's remarks in my opinion may be political in nature and also it is an internal affairs of the country in view of their financial constraints and the safety whether to use the vaccine. Is nothing to do with China vaccine.
22/10/2020 7:17 AM
Chrizleon19 The bull won’t be running yet. Trade accordingly to own discretion .
22/10/2020 7:25 AM
Keyman188 AstraZeneca shares turn negative after Brazilian health authority says volunteer in Covid vaccine study dies

(PUBLISHED WED, OCT 21 20201:15 PM EDTUPDATED 35 MIN AGO)

~ AstraZeneca shares turned negative after a Brazilian health authority, Anvisa, said a volunteer in its coronavirus vaccine study died.

~ The Federal University of Sao Paulo, which is helping coordinate late-stage trials in Brazil, separately said that the volunteer was Brazilian, according to Reuters.

~ The news comes as the Food and Drug Administration still has a late-stage clinical trial from AstraZeneca on hold in the United States.


AstraZeneca shares turned negative Wednesday after a Brazilian health authority, Anvisa, said a volunteer in its coronavirus vaccine study died.

The Federal University of Sao Paulo, which is helping coordinate late-stage trials in Brazil, separately said that the volunteer was Brazilian, according to Reuters.

Shares of AstraZeneca, a front-runner in the Covid-19 vaccine race, gave up a slight gain after the news broke. Shares were down by about 1% in early afternoon trading.

A spokesperson from AstraZeneca declined to comment on the volunteer, citing “medical confidentiality and clinical trial regulations.”

The spokesperson added that ”[a]ll significant medical events are carefully assessed by trial investigators” and ”[t]hese assessments have not led to any concerns about continuation of the ongoing study.”

In a statement, a spokesperson from the University of Oxford, which is developing the vaccine with AstraZeneca, said “there have been no concerns about safety of the clinical trial” after an assessment of the case in Brazil.

“The independent review in addition to the Brazilian regulator have recommended that the trial should continue,” Oxford spokesperson Alexander Buxton said.

Oxford provided no further details on the volunteer’s death, and it’s unclear if the volunteer received the vaccine. Brazil currently has the second deadliest outbreak in the world, behind the United States, with at least 115,914 deaths, according to data compiled by Johns Hopkins University.

A source familiar with the situation told Reuters that the trial would have been suspended if the volunteer had been a part of the group getting the shot.

The news comes as the Food and Drug Administration still has a late-stage clinical trial from AstraZeneca on hold in the United States. That means the company is unable to administer second doses of its two-dose vaccine regimen to U.S. participants.

The company announced on Sept. 8 that its trial had been put on hold due to an unexplained illness in a patient in the United Kingdom. The patient is believed to have developed inflammation of the spinal cord, known as transverse myelitis. The trial has since resumed in the U.K. and other countries.

The U.S. is expected to resume the trial as early as this week after the FDA completed its review, Reuters reported Tuesday, citing four anonymous sources.

AstraZeneca is one of four drugmakers backed by the U.S. in late-stage testing for a potential vaccine. AstraZeneca’s vaccine, called AZD1222, uses genetic material from the coronavirus with a modified adenovirus.

In July, the company published data that showed its vaccine produced a promising immune response in an early-stage trial and appeared to be well tolerated.

The vaccine produced no serious adverse events in volunteers, according to the researchers at the time. Fatigue and headache were the most commonly reported side effects, they said. Other common side effects included pain at the injection site, muscle ache, chills and a fever.


##https://www.cnbc.com/2020/10/21/astrazeneca-shares-slide-after-brazilian-health-authority-says-volunteer-in-covid-vaccine-study-dies.html
22/10/2020 8:26 AM
Plantermen China vaccine strongly tipped to be Malaysia choice. Indonesia already pre book with China state owned lab
22/10/2020 8:28 AM
Keyman188 R.I.P....to heard that...

AstraZeneca's vaccine still not yet reach the safety consumption level...




Posted by Keyman188 > Oct 22, 2020 8:26 AM | Report Abuse X

AstraZeneca shares turn negative after Brazilian health authority says volunteer in Covid vaccine study dies

(PUBLISHED WED, OCT 21 20201:15 PM EDTUPDATED 35 MIN AGO)

~ AstraZeneca shares turned negative after a Brazilian health authority, Anvisa, said a volunteer in its coronavirus vaccine study died.

~ The Federal University of Sao Paulo, which is helping coordinate late-stage trials in Brazil, separately said that the volunteer was Brazilian, according to Reuters.

~ The news comes as the Food and Drug Administration still has a late-stage clinical trial from AstraZeneca on hold in the United States.
22/10/2020 8:44 AM
yongyong88 big funds and insiders are buying. Swim with the big boys...
22/10/2020 8:50 AM
face All Vaccines related counter limit down...??
All Vaccines related counter limit down...??
https://edition.cnn.com/2020/10/21/health/covid-19-vaccine-trial-brazil-astrazeneca-death-bn/index.html
22/10/2020 8:51 AM
yongyong88 hope all vaccine stocks can limit down so can collect more. and ...more.let's pray n wait
22/10/2020 8:54 AM
yongyong88 waiting for limit down...another 5 minutes to opening....waiting to BUY MORE...
22/10/2020 8:55 AM
stocktrade101 all vaccine anf glove stocks up la,

https://www.globaltimes.cn/content/1204263.shtml
22/10/2020 9:12 AM
Mynameisntimportant May i know why you guys like dpharma so much? Anything make you think this is beneficial from the cov vaccine, any agreement signed so far? Pleass share link below
22/10/2020 9:17 AM
stocktrade101 it's just hype, nothing special about Malaysia's pharma companies.
22/10/2020 9:19 AM
Godofgambler Going to fly soon!!!
22/10/2020 9:38 AM
JuYeoh 中国领导层一贯作风是低调保守 只有在万无一失的情况下 才敢发布有关疫苗接种的成功效应 并(且早已经实施在广大人民身上)
22/10/2020 9:52 AM
stocktrade101 ya, but what's that got to do with dpharma and how much can dpharma make from distributing chinese vaccines (if ever) and are these halal vaccines?
22/10/2020 10:14 AM
taiwengyew Halal is more important or life Is more important? Most of thing is not halal. Our money materials also not Halal also vri
22/10/2020 10:18 AM
JuYeoh Mass inoculation was carried out in Wu Han China since 16/3/2020, the result of it - well: 'almost perfect '.
22/10/2020 10:21 AM
JuYeoh 我们真心感谢全世界的医学专才日以继夜的研发疫苗 造福全人类-无论是来自任何国家或机构。我们大大庆幸祝贺中国的成功的同时 更不忘鼓励祝福那些在研究路上遭遇挫折考验的研究机构,再接再厉,不怕慢 一步一脚印,总有成功的一天。再次感恩。
22/10/2020 10:41 AM
bigby7 Aiyoyo... Thanks to whoever that bought my early morning price ya..

My dog will enjoy a good treat..
Tips terang terang bagi tak mau..
22/10/2020 11:21 AM
bigby7 Now is the time to collect at even a lower price.. Time to park my bus low low for all of you. I am a very honest IB
22/10/2020 11:23 AM
Plantermen Vaccines are all classified halal { blood donation} but fill & process production in Malaysia is meant for export to Muslim Arab nations. China has no qualm using Malaysia as a distribution hub. Look at Geely using Proton production hub
22/10/2020 11:30 AM
TenEyeTiger The astra zenica case. The deceased was given a placebo (meningitis vaccine instead of experimental covid 19 vaccine), caught covid 19 in the process and died. Quote:Washington Post

https://www.washingtonpost.com/world/the_americas/coronavirus-oxford-astrazeneca-vaccine-trial-death/2020/10/21/3f5bedac-13c0-11eb-ad6f-36c93e6e94fb_story.html
22/10/2020 11:45 AM
kentrade888 Don't worry about the safety of Chinese vaccines.
22/10/2020 12:12 PM
henry888 Those not comfortable better stay aside/don't buy, don't ask stupid questions ?
22/10/2020 1:20 PM
James89 The Brazilian newspaper O Globo, citing unnamed sources, reported that the volunteer was in a control group that did not receive the experimental vaccine and died of covid-19. The news service G1 said the volunteer was a 28-year-old physician who treated coronavirus patients in Rio de Janeiro.
22/10/2020 1:49 PM
DrJoel88 Time to collect profits for now. Poor vaccine performance in Korea and Brazil. Deaths reported.
22/10/2020 1:58 PM
James89 Deceased AstraZeneca Trial Volunteer Didn’t Receive Vaccine

https://www.google.com.my/amp/s/www.bloomberg.com/amp/news/articles/2020-10-21/astrazeneca-dips-on-report-of-brazil-death-in-vaccine-trial
22/10/2020 5:18 PM
Plantermen Fake news
22/10/2020 7:03 PM
NoNonsenseHere -
Supermax's fair price is RM20. RM25 next 3 months. Why?
Because it is still a small company. Maybank market cap is RM80 billion. Supermax's market cap is only 25 billion.
Maybank market cap (80b) is THREE TIMES larger than Supermax (26b) but Supermax defeats Maybank's profits. Fantastic.

Supermax's profits this coming quarter (Oct 28) is expected to hit RM1 billion which is HIGHER than Maybank's RM940 million only previous quarter.
Fantastic.

Harta's boss said in an interview:
"Glove supply will not meet demand in next three years"
Supermax's QR on Oct 28 expected to hit RM1 billion easily.

This means that Supermax can hit RM1 billion to 1.5 billion+ in profits EVERY QUARTER for years to come, thereby making it the size of Public Bank.

Supermax's Canada OBM Aurelia Gloves™: https://aureliagloves.com/about/

Supermax OBM Mask BeyondMask™: https://mybeyondmask.com/
22/10/2020 7:52 PM
NoNonsenseHere The naysayers say, "HOW CAN SUPERMAX EARN RM1 BILLION IN ONE QUARTER?"

The answer:

Supermax's Canada OBM Aurelia Gloves™: https://aureliagloves.com/about/

Supermax OBM Mask BeyondMask™: https://mybeyondmask.com/

Supermax's is earning USD and Canadian Dollars with their own brand marketing and huge production capacity of gloves and masks.

Maybank market cap (80b) (RM940 million profit previous quarter) is THREE TIMES larger than Supermax (26b) (RM1 billion profit Oct 28 QR) but Supermax defeats Maybank's profit.
22/10/2020 7:54 PM
trade101 Why spamming supermx here??
22/10/2020 8:33 PM
Flytothesky2 https://www.chinapress.com.my/20201022/韩接种流感疫苗-死亡增至10人-皆来自国产疫苗/
23/10/2020 2:36 AM